阿替利珠单抗巩固治疗用于R-CHOP后完全缓解的高危弥漫性大B细胞淋巴瘤患者
这项2期开放标签试验评估阿替利珠单抗巩固治疗能否降低高危弥漫性大B细胞淋巴瘤患者经R-CHOP后达完全代谢缓解的复发风险。109例IPI评分≥3且达完全代谢缓解的患者接受阿替利珠单抗1200 mg每3周共18个周期。2年无病生存率为87.9%,达到主要终点,总生存优于荷兰癌症登记匹配对照队列。
要点
- 高危弥漫性大B细胞淋巴瘤经R-CHOP后完全代谢缓解者2年无病生存率87.9%。
- 阿替利珠单抗1200 mg每3周共18个周期,65%患者完成治疗。
- 不良事件发生率79%,免疫相关不良事件18%,3至4级4.5%。
核心结论
- 阿替利珠单抗巩固治疗较历史队列显著改善高危弥漫性大B细胞淋巴瘤患者的无病生存,总生存优于荷兰癌症登记匹配对照队列。
- 作者认为这些发现需进一步验证和评估免疫检查点抑制剂作为弥漫性大B细胞淋巴瘤的巩固策略。
研究设计与样本
- 2期开放标签试验,纳入R-CHOP后达完全代谢缓解且IPI评分≥3的弥漫性大B细胞淋巴瘤患者109例。
- 阿替利珠单抗1200 mg每3周共18个周期,主要终点为2年无病生存率,目标提升至89%(历史对照79%)。
- 次要终点包括总生存和安全性(不良事件通用术语标准4.0版),按意向性治疗原则分析。
- 试验注册号NCT03463057。
主要发现
- 109例患者中65%完成治疗,男性占59%,63%为高中危IPI评分。
- 中位随访36.4个月时发生15例复发(中位8.2个月),2年无病生存率87.9%(90% CI 81.5-92.1),2年总生存率96.3%(90% CI 91.7-98.3),达到主要目标。
- 挽救化疗使13例患者中10例再次达完全代谢缓解。
- 阿替利珠单抗治疗患者总生存显著优于荷兰癌症登记匹配对照队列。
- 不良事件发生率79%,18%发生免疫相关不良事件,其中3至4级占4.5%。
局限性
- 作者认为这些发现需进一步验证和评估免疫检查点抑制剂作为弥漫性大B细胞淋巴瘤的巩固策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The risk of relapse among high-risk patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission (CMR) after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy is 20% to 25%. Here, we evaluated whether consolidation with the programmed cell death ligand 1 checkpoint inhibitor atezolizumab could reduce the relapse risk. In this phase 2, open-label trial, patients with DLBCL with an International Prognostic Index (IPI) score of ≥3 and CMR after R-CHOP received 1200 mg atezolizumab every 3 weeks for 18 cycles. The primary end point was disease-free survival (DFS) at 2 years, with the aim of improving it to 89% compared to historical 79%. Secondary end points included overall survival (OS) and safety (Common Terminology Criteria for Adverse Events version 4.0). Analyses were on an intention-to-treat principle. Of 109 patients, 65% completed treatment. The cohort was 59% males, with 63% having high-intermediate risk IPI scores. At a median follow-up of 36.4 months, 15 relapses occurred (median, 8.2 months). The 2-year DFS was 87.9% (90% confidence interval [CI], 81.5-92.1), and the 2-year OS was 96.3% (90% CI, 91.7-98.3), meeting the primary objective. Treatment with salvage chemotherapy resulted in 10 of 13 patients achieving a second CMR. OS was significantly better among atezolizumab-treated patients than in a population-based matched control cohort from the Netherlands Cancer Registry. Adverse events (AEs) affected 79% of patients, with 18% developing immune-related AEs, including 4.5% grade 3 to 4. Atezolizumab consolidation significantly improved DFS in high-risk patients with DLBCL compared to historical cohorts. OS was significantly better than a population-based control cohort. These findings warrant further validation and assessment of immune checkpoint inhibitors as consolidation strategy in DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT03463057.
引用
- Nijland M, Issa DE, Bult JAA, et al. Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP. Blood Adv. 2025. PMID: 40249860. doi:10.1182/bloodadvances.2024015226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。